Cautious Report Unlikely To Slow Partial-Breast Irradiation Market, Firms Say
This article was originally published in The Gray Sheet
Executive Summary
In its most recent assessment of accelerated partial-breast irradiation (APBI), the BlueCross BlueShield Association Technology Evaluation Center reiterated that APBI as the sole radiation treatment following breast-conserving surgery for early stage cancer has not been proven beneficial. But companies in the budding APBI market say the report does not deter them from marketing or developing their treatments (see chart: "1FDA-Cleared APBI Devices ")
You may also be interested in...
People In Brief
STERIS CEO: Walter M. Rosebrough Jr. is named president and CEO of the sterilization systems manufacturer, effective Oct. 1. Rosebrough replaces Les C. Vinney, who announced plans to step down last year. Vinney will continue to serve as special advisor to the company until his retirement in 2009. Rosebrough has more than 20 years experience in the health care industry, including top positions as Hill-Rom and health care start-up Vasocor. He is stepping down as president and CEO of family-owned Coastal Hydraulics
People In Brief
STERIS CEO: Walter M. Rosebrough Jr. is named president and CEO of the sterilization systems manufacturer, effective Oct. 1. Rosebrough replaces Les C. Vinney, who announced plans to step down last year. Vinney will continue to serve as special advisor to the company until his retirement in 2009. Rosebrough has more than 20 years experience in the health care industry, including top positions as Hill-Rom and health care start-up Vasocor. He is stepping down as president and CEO of family-owned Coastal Hydraulics
Proxima MammoSite RTS For Early-Stage Breast Cancer To Launch By May 17
Proxima Therapeutics will emphasize its single-catheter MammoSite radiation therapy system's ease of use over multi-catheter competitor devices in treating early-stage breast cancer